TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03590574

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO4
Description: AUTO4 (RQR8/aTRBC1 CAR T cells) Following pre-conditioning with chemotherapy (cyclophosphamide and fludarabine), patients will be treated with doses from 25 to 900 x 10\^6 RQR8/aTRBC1 CAR T cells in Phase I. Following dose determination patients will be treated with the selected doses of RQR8/aTRBC1 CAR T cells (AUTO4) in Phase II.
Study: NCT00667485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin (liquid)
Description: Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin (Tablets)
Description: Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
Study: NCT02632604

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training
Description: 40 hours of a computerized cognitive training, given 1 hour daily

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer games
Study: NCT02473731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KTN3379
Study: NCT00541177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atropine
Description: 0.25% atropine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tropicamide
Description: 0.5% tropicamide
Study: NCT01791075

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tan Endoglide
Description: Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosaver
Description: Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
Study: NCT01008865

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Studer Pouch orthotopic urinary diversion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-Pouch orthotopic urinary diversion
Study: NCT02917603

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Conferencing
Description: Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
Study: NCT03449901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated arginine deiminase
Description: -Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated arginine deiminase
Description: -Arginine deiminase (ADI) is a recombinant protein cloned from M. hominis, produced in E. coli, and conjugated with PEG of 20,000 mw using a succinimidyl succinate linker. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: -Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: -Gemcitabine is a nucleoside metabolic inhibitor that exhibits antitumor activity.
Study: NCT02319252

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric tube (Nutricia Flocare® Pur Tube Enlock)
Description: Nutricia Flocare® Pur Tube Enlock, Ch. 12

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jejunal tube (Nutricia Flocare® Bengmark®)
Description: Nutricia Flocare® Bengmark®, Ch. 10
Study: NCT00523770

Intervention type: PROCEDURE
Intervention: Urine sample collection
Description: Urine samples will be collected and tested for the presence of S. pneumoniae
Study: NCT02675764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration
Description: peripheral vibration at the wrist skin at an imperceptible level

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for vibration)
Description: No peripheral vibration at the wrist skin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: therapy
Description: standardized hand therapy program
Study: NCT03449901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: -Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: -Docetaxel is an antineoplastic agent belonging to the taxoid family. It is prepared by semisynthesis beginning with a precursor extracted from the renewable needle biomass of yew plants.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * Up to 21 days prior to initiation of ADI-PEG 20 Day -1 (+/- 1 day as long as performed prior to initiation of gemcitabine.~* Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only (completed as of 05/14/2019) and for all patients enrolled to the SCLC cohort
Study: NCT02675764

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: therapy
Description: standardized hand therapy program
Study: NCT01707641

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CD#2
Description: patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bicarbonate sodium mouthwash
Description: Patients will be asked to wash their mouth with bicarbonate sodium several times per day
Study: NCT01398852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: Riboflavin is a solution that will be delivered to the treatment area
Study: NCT03449901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: * Up to 21 days prior to initiation of ADI-PEG 20 Day -1 (+/- 1 day as long as performed prior to initiation of gemcitabine.~* Tumor biopsies are mandatory for the first 20 patients amendable to biopsy enrolled at Washington University only (completed as of 05/14/2019) and for all patients enrolled to the SCLC cohort

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
Study: NCT01398852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEGA UV-A Illumination System
Description: This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
Study: NCT03281746

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Procedure
Description: Undergo dental examination

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Procedure
Description: Undergo dental examination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention (prevention education)
Description: Receive prevention education
Study: NCT03449901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: -Day -7 (pre-treatment), Day -1, and Days 1 and 8 of each cycle
Study: NCT03808818

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive information about tobacco cessation
Study: NCT03281746

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (prevention education)
Description: Receive prevention education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention (one-on one education)
Description: Receive one-on-one education
Study: NCT01082679

Intervention type: DRUG
Group type: OTHER
Intervention: Methadone
Description: daily for 12 months

Intervention type: DRUG
Group type: OTHER
Intervention: buprenorphine (Suboxone)
Description: daily for 12 months

Intervention type: DRUG
Group type: OTHER
Intervention: buprenorphine (Suboxone)
Description: daily for 12 months
Study: NCT03082027

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: ultrasonography of median nerve

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasonography
Description: ultrasonography of median nerve
Study: NCT04649879

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 convalescent plasma
Description: Participants will receive 200 ml convalescent plasma daily until SARS-CoV-2 is no longer detectable in the blood up to a maximum of 10 CP infusions. CP will be given as a slow infusion over 2 hours. CP neutralization titre of ≥ 1/640 or an ELISA reactivity against the Spike protein of SARS-CoV-2 by the Euroimmun commercial assay \>9 is desired. New antibody tests are under development and can be used instead if equivalence to neutralization or Euroimmun ELISA is demonstrated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care as determined by hospital practices for COVID-19 patients.
Study: NCT02250300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708 (2.3 mg)
Description: 2.3 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708 (4.0 mg)
Description: 4.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708 (4.0 mg)
Description: 4.0 mg
Study: NCT03808818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Given NRT patch or lozenge (or both)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT02250300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708 (4.0 mg)
Description: 4.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708 (3.0 mg)
Description: 3.0 mg
Study: NCT02855775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Description: blood sample every 3 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Description: blood sample every 3 weeks
Study: NCT00630799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: 17 mg i.m.
Study: NCT01278602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-ESHAP
Description: Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
Study: NCT01557673

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NG bolus feeding over 5 min
Description: Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Continuous NG feeding over 4 h
Description: Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
Study: NCT03659123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standardized geriatric intervention
Description: Nutritional care is based on:~* A personalized evaluation of nutritional balance and nutritional needs of the patient~* A weekly follow-up of weight and nutritional intake~Total-body rehabilitation is based on:~* 2 to 3 times a week: strength exercise~* 2 to 3 times a week: endurance exercise, 20 to 45 min each sequence~* 2 times a week: respiratory physiotherapy Pharmaceutical conciliation and optimization according STOPP/START criteria During peri-operative time, the nurse contacts the surgical team for transmission of patient's personal data, physical medication conciliation results During rehabilitation time and hospital-home transition time, the nurse contacts the rehabilitation team for transmission of patient's personal data and care course, physical (nutritional, functional and/or comorbidities), medication conciliation results.
Study: NCT00954122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (Seroquel XR)
Description: Tablet, oral, once daily
Study: NCT03380871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NEO-PV-01
Description: Personal Cancer Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: monoclonal antibody against PDL1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjuvant
Description: immune adjuvant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: chemotherapy
Study: NCT02699996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete interview

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Complete the self management + peer mentoring intervention with videoconferencing
Study: NCT01781208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)
Description: Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
Study: NCT02898857

Intervention type: OTHER
Intervention: biopsies
Description: The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma

Intervention type: OTHER
Intervention: biopsies
Description: The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma

Intervention type: OTHER
Intervention: biopsies
Description: The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
Study: NCT01060189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Study: NCT02019342

Intervention type: OTHER
Intervention: FACE quality improvement initiative (see below)
Description: Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.

Intervention type: OTHER
Intervention: Pre-quality improvement initiative
Description: Patients in the pre-quality improvement initiative arm would receive current standard practice.
Study: NCT02073526

Intervention type: DRUG
Intervention: Infliximab, adalimumab, certolizumab pegol
Description: Patients are treated with the above mentioned drugs decided by clinicians
Study: NCT01991964

Intervention type: OTHER
Group type: OTHER
Intervention: laryngeal ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laryngeal ultrasound
Study: NCT03151447

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.~Stereotactic body radiation therapy: SBRT is delivered to 1\~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .~Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks.
Study: NCT00929994

Intervention type: BEHAVIORAL
Intervention: Cardiac Rehabilitation
Description: Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
Study: NCT01808274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards CENTERA Self-Expanding Transcatheter Heart Valve
Description: The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
Study: NCT01442012

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ear seeds
Description: The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ear seeds
Description: The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
Study: NCT03808818

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive virtual tobacco cessation counseling
Study: NCT01343862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
Study: NCT01506973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study: NCT00249964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Treatment - Cohort 1
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 75 mg/m2 per day from day 2 to day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Treatment - Cohort 2
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 100 mg/m2 per day from day 2 to day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Treatment - Cohort 3
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 125 mg/m2 per day from day 2 to day 6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Treatment - Cohort 4
Description: Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.~Temozolomide at 150 mg/m2 per day from day 2 to day 6.
Study: NCT03460808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin was used in combination with acetylcysteine and danazol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcysteine was used in combination with atorvastatin and danazol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol was used in combination with atorvastatin and acetylcysteine or as the monotherapy
Study: NCT01840410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
Study: NCT04515433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma tACS (40 Hz) over the superior parietal cortex
Description: Single session of gamma tACS (40 Hz) over the superior parietal cortex

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gamma tACS (40 Hz) over the superior parietal cortex
Description: Single session of gamma tACS (40 Hz) over the superior parietal cortex